Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gap between .3443 - .3605 Gonna get my bid (fingers crossed) Good one to hold onto for a while
Peeps going to figure out soon it’ll run to the moon
There is something seriously wrong in this company.
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
- Compared to monomeric IL-15, GTB-5550 shows CD16-dependent metabolic activation of NK cells
BEVERLY HILLS, Calif., Dec. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (GTBP) (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the Company's mini-poster presentation abstract is now broadly available on the European Society for Medical Oncology ("ESMO") Immuno-Oncology ("IO") Congress (CACOX) 2021 abstracts webpage. The congress is being held from December 8-11, 2021, in Geneva Switzerland.
https://mma.prnewswire.com/media/1483265/GTBP_SmallLogo_Logo.jpg
"B7-H3 is a checkpoint molecule under intense investigation as an immune therapy target for solid and hematologic tumors. These proof of concept data via in vivo animal models validates GTB-5550's candidacy for further investigation, noted Dr. Gregory Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer. GT BioPharma's diverse but focused pipeline of TriKE® Nanobodies are highly targeted natural killer cell engagers, resulting in potent activation, proliferation, and persistence of the patient's NK cells, without activation of T-cells, which are often responsible for the side effects of T-cell directed therapies. As such, we look forward to continuing the Company's progress in the new year including the advancement of GTB-3650, second-generation TRIKE® for patients with relapsed/refractory Acute Myelogenous Leukemia (AML) and high-risk Myelodysplastic Syndrome (MDS)."
The study was conducted by Dr. Jeff Miller's lab, University of Minnesota where functional assays were conducted with various ovarian, prostate, and hematologic malignancy cell lines with varying levels of B7H3 expression from none to very high levels. Dr. Miller's lab previously showed that dual camelid nanobody tri-specific killer engager (TriKE) (GTB-5550) specifically bound B7-H3 on PC3/C4-2 prostate cancer (PCa) cells and activated peripheral blood (PB) NK cells. We have since developed a dual camelid bispecific killer engager (BiKE) targeting B7-H3 and show that both GTB-5550, which harbors wild-type IL-15, and BiKE display broad activity against B7-H3-expressing tumors. Compared to monomeric IL-15, GTB-5550 shows CD16-dependent metabolic activation of NK cells.
Presentation highlights from the mini-poster titled, "Novel B7-H3 Targeting Dual-Nanobody NK Cell Engagers Display Robust Activity" include:
Study Background
BiKE and GTB-5550 were manufactured in a mammalian expression system and purified from supernatants.
Models were used to evaluate how the BiKE and GTB-5550 induce NK cell degranulation (CD107a) and interferon gamma production through a variety of cell lines including PCa cells harboring enzalutamide resistance with divergent mechanisms including 22RV1 (androgen ligand-independent AR-V7 splice variant) as well as a spontaneously resistant LNCaP model (AR hyper activation), as well as a CREB5 overexpressing (epithelial to mesenchymal transition) LNCaP model.
Metabolic stimulation was measured in NK-92 cell lines.
PB NK cells were robustly activated, compared to controls, when treated with GTB-5550 or BiKE and cultured with enzalutamide resistant PCa, osteosarcoma (U2OS, SaOS2), rhabdomyosarcoma (RH30), ovarian carcinoma (MA148, OVCAR8), AML (MV4;11, THP-1) and multiple myeloma (MM1S) cell lines.
GTB-5550 was approximately 2 times more potent than NCI IL-15 in terms of metabolic stimulation of CD16+ NK-92 cells, but not CD16- NK-92 cells. Spheroid killing assays and deeper metabolic analyses are in progress.
Results of the Study
The data demonstrated that the novel dual camelid nanobody BiKE and GTB-5550 induce NK cell activation against a broad spectrum of tumors expressing B7-H3. Furthermore, B7-H3 is expressed at high levels on prostate cancer cell lines demonstrating enzalutamide resistance, thus inducing efficient targeting of these therapy PCa refractory lines. This B7-H3 targeting NK platform demonstrates broad translational potential. GMP production of GTB-5550 has been initiated.
ESMO IO 2021 presentation details
e-Poster Display Title (#126P): Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies
The full abstract has been published on ESMO-IO website and the Company has published the poster on the company's website in the "Presentations" section of its corporate website.
For event details please visit: https://www.esmo.org/meetings/esmo-immuno-oncology-congress-2021/programme
About Camelid Antibodies
Camelid antibodies are single domain antibodies (sdAbs) from the Camelidae family of mammals that include llamas, camels, and alpacas. These animals produce 2 main types of antibodies. One type of antibody camelids produce is the conventional antibody that is made up of 2 heavy chains and 2 light chains. They also produce another type of antibody that is made up of only 2 heavy chains and no light chain. This is known as heavy chain IgG (hcIgG). While these antibodies do not contain the CH1 region, they retain an antigen binding domain called the VHH region. VHH antibodies, also known as single domain antibodies, contain only the VHH region from the camelid antibody. Camelid antibodies have key characteristics, which include high affinity and specificity (equivalent to conventional antibodies), high thermostability, good solubility and strictly monomeric behavior, small size, relatively low production cost, ease of genetic engineering, format flexibility or modularity, low immunogenicity, and a higher penetration rate into tissues.
About GTB-5550
GTB-5550 TriKE® product candidate is being developed for the treatment of B7H3+ solid tumor cancers. GTB-5550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-B7H3 antibodies and human IL-15.
About GTB-3650
GTB-3650 is the Company's lead second-generation Tri-Specific Killer Engager TriKE® program currently in preclinical development for the treatment of relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Was the CEO and CFO fired for cause? And what was the cause?
Thanks for any reply. I missed the details.
I think the general biotech atmosphere is mostly to blame. Of course firing the CEO and CFO didn't help and there probably won't be any clinical news for about a year, so not surprising really that the share price has suffered.
TAX LOSS SELLING? Or something else?
Negative article on GTBP at Seeking Alpha
Well-written and reasonable.
https://seekingalpha.com/article/4469389-gt-biopharma-shift-therapy-reduces-attractiveness-gtbp-stock
GT Biopharma falls 21% after CEO and CFO leave company
Nov. 08, 2021
By: Jonathan M Block
Shares of GT Biopharma (GTBP -20.7%) are down significantly today after the company said CEO Anthony Cataldo and CFO Michael Handelman have left the company.
The company's board has appointed Gregory Berk and Gavin Choy, respectively, as acting CEO and CFO.
GT also appointed Stacy Herb to SVP, portfolio management, and Leslie Bransfield to VP of chemistry, manufacturing, and control and pharmaceutical sciences.
Year to date, GT shares are down ~4%.
In September, GT was issued two patents covering the company's TriKE platform technologies.
GT Biopharma EPS beats by $0.13
Aug. 26, 2021 GT Biopharma, Inc. (GTBP)
By: Meghavi Singh, SA News Editor
GT Biopharma (NASDAQ:GTBP): Q2 GAAP EPS of -$0.15 beats by $0.13.
Cash and cash equivalents of $39.51M as of June 30, 2021.
a W shape is forming. We may finally be out of the woods.
GT Biopharma announces strong early-stage safety results for blood cancer therapy
Jun. 23, 2021
By: Dulan Lokuwithana, SA News Editor
Cancer cells
GT Biopharma (GTBP +6.0%) announced interim results from a Phase 1 trial for the company’s recombinant fusion protein conjugate, GTB-3550 in the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML).
With 11 patients completing the treatment, GTB-3550 was well-tolerated with no cytokine release syndrome detected, the company said.
57% of patients were found to have a significant reduction in AML/MDS cancer cells at doses ranging from 25mcg/kg/day to 150mcg/kg/day. Some patients had a 63.7% reduction in bone marrow blast levels.
“In addition to strong safety results, we have seen significant reductions in CD33+ cancer cells in four of the last seven patients (57%) treated with doses of GTB-3550 ranging from 25mcg/kg/day to 150mcg/kg/day,” noted GT Biopharma CEO, Anthony Cataldo.
In April, GT Biopharma announced the appointment of industry veteran and its former board member Gregory Berk as the new chief medical officer.
GTBP to be added to Russell 2000 by June 28, 2021!!
This stock has barely 1% demand and it keeps going up. I wonder what will happen if we have 10% or more of O/S volume.
GT Biopharma a new buy at H.C. Wainwright
The platform used by GT Biopharma (NASDAQ:GTBP) “constitutes a precision medicine assembly line” notes H.C. Wainwright analyst Robert Burns in initiating the coverage on the stock with a buy rating. The price target of $25.00 per share indicates an upside of ~74.1%.
The company’s candidates based on its proprietary NK cell engager (TriKE) protein biologic technology platform have "the potential to overcome certain limitations of CAR-T therapy, emerging cell-based immunotherapy approaches and other antibody therapies,” the analyst wrote.
In April, GT Biopharma appointed Gregory Berk a 30 year veteran in oncology drug development as its new chief medical officer.
All share price moves are calculated based on the market close unless otherwise stated.
Got in at $9.25 just a couple of weeks ago. Very happy with the progress in GTBP.
Most likely before if they are
Bought out....
The price move has been very impressive
as it moves higher...
Pretty impressive patient results. Once they expand to larger trials and replicate these one patient results, GTBP will get more research coverage.
When is their next conference they are going to? Would not be surprised if we pull back to $8 or so until they have more news on their patient trials.
You were absolutely right .... love to see the new investors comming on board and moving the price
Did you hear of the Beverly Hillbillies?
Their headquarters is in beverley hills
Big money there
Have just asked PR if they can provide me the ppt or webcast. Will let you know if I got any respond.
Has anyone been able to track down the GTBP presentation at the Roth conference last week?
Once we get fda approved this is footing go over $25
You know this is going much higher
Today and tomorrow another big jump
Need the big buyers to knock out the shorts
This should close above $8.00 today
Got the news yesterday in an email. Maybe somebody read the actual study results and said to buy, game changers are out there and here's one now.
Bidding $2.49 here
i have been there before ! most reverse splits dont return the investors to previous levels . i have found it to be less than half. good luck all.
i have been there before ! most reverse splits dont return the investors to previous levels . i have found it to be less than half. good luck all.
With phase I coming to an end by end of Q2, this one will easily go to $20.
Today was a solid return. I expect many happy returns. #holding
If you have a small position that would be reasonable.
I’m still ahead on my position (principal) post reverse split.
So I’m ahead already and looking forward to what GTBP
has to offer after raising $$$$ for their venture.
I’m anticipating it will open higher, and eventually see the
street taking notice..
Good luck.
Followers
|
170
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
18649
|
Created
|
04/04/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |